NRXP
NRx Pharmaceuticals, Inc.
There isn't enough reported data to score NRXP yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NRXP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
NRXP's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NRXP PE Valuation
NRXP has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NRXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NRXP's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over NRXP on the outlook, with more favorable earnings and profitability expectations.
NRXP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$2.29 | -$0.12 |
| Q2 2025 | -$2.17 | +$0.55 |
| Q1 2025 | -$1.94 | +$1.23 |
| Q4 2024 | -$2.36 | +$1.67 |
| Q3 2024 | -$2.17 | +$2.83 |
| Q2 2024 | -$2.72 | +$2.98 |
| Q1 2024 | -$3.17 | +$2.43 |
| Q4 2023 | -$4.03 | +$1.97 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 206% for NRXP versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NRXP Quarterly Revenue
NRXP's revenue has grown year over year every quarter since late 2025: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -591% | N/A |
| Q1 2026 | -444% | N/A |
| Q4 2025 | -470% | N/A |
| Q3 2025 | -1663% | N/A |
OSCR has the edge over NRXP on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NRXP on profitability, with a higher operating margin.
NRXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$815K |
| Q4 2025 | -$3.7M | -$1.6M |
| Q3 2025 | -$2.9M | -$585K |
| Q4 2024 | -$2.1M | +$1.1M |
| Q3 2024 | -$2.3M | +$2.3M |
| Q4 2023 | -$3.2M | +$5.1M |
| Q3 2023 | -$4.6M | +$1.7M |
| Q2 2023 | -$7.8M | +$7M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with NRXP at up 25%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NRXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +5.3M shares |
| 1 year | +118% | +20.4M shares |
| 3 years | +472% | +31.1M shares |
| 5 years | +13858% | +37.4M shares |
| Available history | +13340% | +37.4M shares |
NRXP has 38M diluted shares, up 118% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | $299,253 |
| Q2 2020 | — |
| Q1 2020 | $26M |
| Q3 2019 | $8.9M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over NRXP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NRXP Net Leverage
NRXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NRXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 10.6 | Oversold |
NRXP's weekly RSI is 36 (neutral) and its Stochastic is 11 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NRXP PE vs Healthcare Sector
| Metric | NRXP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NRXP has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NRXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.60 | 12% below |
| 20 week MA | $3.21 | 29% below |
| 50 week MA | $2.85 | 20% below |
| 100 week MA | $2.78 | 18% below |
| 200 week MA | $3.47 | 34% below |
NRXP is in a downtrend: it's below all five of its weekly moving averages, and 34% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NRXP on trend strength, trading above more of its moving averages.
NRXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $106.5 | $296.4 | +178% |
| 2021 | $296.4 | $50.4 | -83% |
| 2022 | $50.4 | $10.8 | -79% |
| 2023 | $10.8 | $4.60 | -57% |
| 2024 | $4.60 | $1.51 | -67% |
| 2025 | $1.51 | $2.56 | +70% |
| 2026 YTD | $2.56 | $2.28 | -11% |
NRXP's yearly returns have swung widely, from +178% in 2020 to −83% in 2021. It's down 11% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NRXP on returns for 2026, with the stronger performance.